Search Results
Results found for "Juan Jose Fung"
- Re-cap of Endocrine Metabolic GPCR 2024 with the Organizers | Dr. GPCR Ecosystem
Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes
- Beatriz Blanco-Redondo: Adhesion GPCR Discovery in Drosophila | Dr. GPCR Ecosystem
Remulate is the receptor she secured funding to study, the one her first PhD student built an entire discuss the cost of unpublished negative data - particularly for PhD students working within three-year funding
- YC-VC Insights | Dr. GPCR Ecosystem
Track My Discovery The wrong CRO—or wrong experiments—can burn months and millions You're not here to fund
- Paul Insel: Unbiased Discovery and the GPCRs We've Been Missing | Dr. GPCR Ecosystem
The "unknown unknowns" should change how we fund and train scientists Dr. GPR68 and the feedback loop in pancreatic cancer 19:46 Challenges of targeting GPCRs in oncology — funding
- Pfleger: NanoBRET, Receptor Complexes, and the Translation of GPCR Pharmacology | Dr. GPCR Ecosystem
design for GPCR biology Academic entrepreneurship and the path from bench to phase 2 clinical trials Funding The spin-out - how a discovery became a phase 2 clinical trial in kidney disease 16:56 Why grant-only funding
- Brian Bender: Computational Probes for Orphan GPCR | Dr. GPCR Ecosystem
endogenous agonist is known, it may be a large peptide or lipidated compound that cannot be practically dosed
- Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox | Dr. GPCR Ecosystem
downregulation and tolerance, while low-internalizing agonists uncouple the receptor from ion channels without losing migraine — a path through four labs 04:19 Why mu worsens migraine and delta relieves it 09:27 What chronic dosing
- Scaling GLP 1 Receptor Tools Through Academia Industry Collaboration | Dr. GPCR Ecosystem
Why This Matters How GPCR tools lose impact when distribution and access aren’t planned from the start scientific activities, from proprietary technology development to international collaborations and funded
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
The "brain always wins" problem is solved by isoform selectivity, not by dose.
- Dr. Michael Feigin | Dr. GPCR Ecosystem
dosage and length of treatment in a mouse model and suggested using a biosensor-based assay to examine dose-response
- Ross Cheloha: Nanobody-GPCR Conjugates and the Engineering of Receptor Selectivity | Dr. GPCR Ecosystem
Tissue-specific targeting as a strategy for reframing side effects The primary dose-limiting side effect
- Custom Molecules, Fluorescent Probes: When Chemists Think Like Biologists with Dr. Maria Majellaro from Celtarys | Dr. GPCR Ecosystem
To date, she has successfully led seven funded projects.
- Elva Zhao: G Protein Regulation and Biased Signaling at the GLP-1 Receptor | Dr. GPCR Ecosystem
primarily nausea and vomiting - remain among the main barriers to broader clinical use and optimal dosing
- Revvity | Dr. GPCR Ecosystem
“When we saw dose-dependent internalization in endogenous GLP1R cells—without microscopy—that was the
- Dr. Aurélien Rizk | Dr. GPCR Ecosystem
They highlighted the strategic importance of planning in the biotech sector due to limited funds and
- Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease | Dr. GPCR Ecosystem
Jan Nedergaard, pioneers in thermogenesis research. Fundamental Limitation Traditional β₂-adrenergic agonists can stimulate muscle growth and fat loss but lose But traditional β₂ agonists lose effectiveness over time because the receptor becomes desensitized. The body adapts, requiring higher doses. That makes them unsuitable as long-term therapeutic drugs.
- Dr. John Janetzko | Dr. GPCR Ecosystem
John suggested building milestones and landmarks into a postdoc, such as applying for funding opportunities
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
Arthur shared his insights into the unique grant funding system in Australia, the importance of impact
- Dr. Arthur Christopoulos | Dr. GPCR Ecosystem
Arthur shared his insights into the unique grant funding system in Australia, the importance of impact
- Chris Tate: Thermostabilizing GPCRs for Structural Biology | Dr. GPCR Ecosystem
from concept to systematic mutation screen From academic discovery to co-founding Heptares: decision, funding
- Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem
GPCR ecosystem 32:28 Q&A — preparing an episode, funding, and what's next 46:53 Recording Brian Roth
- Graciela Piñeyro: Partial Agonism, Receptor Recycling, and the Limits of Bias | Dr. GPCR Ecosystem
In a funding environment that rewards the opposite, the advice is harder to take than it sounds — and
- David Gloriam: Orphan Receptors, GPCRDB, and the Data Revolution in GPCR Pharmacology | Dr. GPCR Ecosystem
before his group was large enough to require it - acting on advice from mentors who recognized that funding And that's the fun part." "I walked in there and I did the best performance ever.
- Qing Fan: Inside the Architecture of Class C GPCRs | Dr. GPCR Ecosystem
and to work on projects that they're passionate about and not simply projects that may attract more funding
- Joseph Kim: Structural Biology and Drug Discovery at GPCRs | Dr. GPCR Ecosystem
you, Joe, to the podcast today. Joe Kim, welcome to the Dr. GPCR podcast. Dr. Joseph Kim: Thank you, Yamina. I go by Joe. So Joe, tell me a little bit about how you ended up working on GPCRs in Ashish’s lab. There’s that saying that the difference between drugs and poisons is often just the dose.
- Vaithish Velazhahan | Dr. GPCR Ecosystem
His Ph.D. work has been focused on understanding the structure and activation of Class D fungal GPCRs He has developed novel tools and methodologies to study fungal GPCRs which allowed the determination of the first structures of the prototypical fungal GPCR Ste2.
- Dr. Nariman Balenga | Dr. GPCR Ecosystem
Druey at NIAID/NIH, where I characterized the role of RGS4 and RGS5 in airway hyperresponsiveness and lung fascinated by the multitude of processes that are regulated/dysregulated by GPCRs and RGS proteins in the lungs seemingly naĂŻve idea at the dinner table led to a side project by which I characterized the impact of a fungal A fungal serine protease allergen with GPCR-modulating features was discovered as a new biomarker and



























